Dergiler / Turkish Journal of Hematology / 2021 / Cilt: 38 - Sayı: 1

Primary Immune Regulatory Disorders and Targeted Therapies

Primer İmmün Regülatuvar Hastalıklar ve Hedeflenmiş Tedaviler

Sayfa
1–14
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this review, in light of the most recent literature, we will discuss the common PIRDs and explain their clinical symptoms and recent treatment modalities.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Primary immune regulatory disorders (PIRDs) are a group of diseases belonging to inborn errors of immunity.
📊
Temel Bulgular & Veri:They usually exhibit lymphoproliferation, autoimmunities, and malignancies, with less susceptibility to recurrent infections.
💡
Sonuç & Katkı:In this review, in light of the most recent literature, we will discuss the common PIRDs and explain their clinical symptoms and recent treatment modalities.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Primary immune regulatory disorders (PIRDs) are a group of diseases belonging to inborn errors of immunity. They usually exhibit lymphoproliferation, autoimmunities, and malignancies, with less susceptibility to recurrent infections. Unlike classical primary immune deficiencies, autoimmune manifestations, such as cytopenias, enteropathy can be the first symptom of diseases, and they are typically resistant to treatment. Increasing awareness of PIRDs among specialists and a multidisciplinary team approach would provide early diagnosis and treatment that could prevent end-organ damage related to the diseases. In recent years, many PIRDs have been described, and understanding the immunological pathways linked to these disorders provides us an opportunity to use directed therapies for specific molecules, which usually offer better disease control than known classical immunosuppressants. In this review, in light of the most recent literature, we will discuss the common PIRDs and explain their clinical symptoms and recent treatment modalities.

Abstract

Primer immündisregülasyon hastalıkları (PİRH), immün sistemin doğuştan gelen bozuklukları içerisinde yer alan bir grup hastalıktır. Çoğunlukla lenfoproliferasyon, otoimmünite ve malignite bulguları sergilerler ve bu grupta tekrarlayan enfeksiyonlara yatkınlık daha az olabilmektedir. Ayrıca diğer klasik primer immün yetmezliklerden farklı olarak otoimmün bulgular (örneğin; sitopeniler, enteropati) hastalığın ilk semptomu olarak çıkabilmekte ve tipik olarak tedaviye direnç gösterebilmektedir. Primer immün disregülasyon hastalıkları hakkındaki farkındalığın artırılması ve multidisipliner yaklaşımlar, erken tanı ve tedaviyi mümkün kılarak, hastalıkla ilişkili gelişebilecek uç-organ hasarlarını önlemeye yardımcı olabilecektir. Son yıllarda, birçok yeni PİRH tanımlanmıştır ve bu hastalıklarla ilişkili immünolojik yolaklarının aydınlatılması bizlere klasik immünosüpresanlar yerine genellikle daha iyi hastalık kontrolü sağlayabilen hedeflenmiş tedavileri kullanma yolunu açmıştır. Bu derlemede, en güncel literatür araştırmaları ışığında, sık rastlanan PİRH’lerin tanımlanması ve bunlarla ilişkili klinik özelliklerin ve yeni tedavi yaklaşımlarının tartışılması hedeflenmiştir.

🔖

Bu Makaleye Atıf Yap

KOLUKISA, B., BARIŞ, S. (2021). Primary Immune Regulatory Disorders and Targeted Therapies. Turkish Journal of Hematology, Cilt: 38 - Sayı: 1, 1–14. https://ajindex.com/articles/399365

Kaynakça (11)

  1. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, Ochs HD, Oksenhendler E, Picard C, Puck J, Torgerson TR, Casanova JL, Sullivan KE. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020;40:24- 64
  2. Walter JE, Ayala IA, Milojevic D. Autoimmunity as a continuum in primary immunodeficiency. Curr Opin Pediatr 2019;31:851-862
  3. Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: an expanding universe. Sci Immunol 2020;5:eabb1662
  4. Baris HE, Kiykim A, Nain E, Ozen AO, Karakoc-Aydiner E, Baris S. The plethora, clinical manifestations and treatment options of autoimmunity in patients with primary immunodeficiency. Turk Pediatri Ars 2016;51:186- 192
  5. Chan AY, Torgerson TR. Primary immune regulatory disorders: a growing universe of immune dysregulation. Curr Opin Allergy Clin Immunol 2020;20:582-590
  6. Baris S, Schulze I, Ozen A, Karakoc Aydiner E, Altuncu E, Karasu GT, Ozturk N, Lorenz M, Schwarz K, Vraetz T, Ehl S, Barlan IB. Clinical heterogeneity of immunodysregulation, polyendocrinopathy, enteropathy, X-linked: pulmonary involvement as a non-classical disease manifestation. J Clin Immunol 2014;34:601-606
  7. Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, Cunningham- Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, Ochs HD, Oksenhendler E, Puck J, Torgerson TR, Casanova JL, Sullivan KE, Tangye SG. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol 2020;40:66-81
  8. Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr 2013;25:708-714
  9. Cepika AM, Sato Y, Liu JM, Uyeda MJ, Bacchetta R, Roncarolo MG. Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. J Allergy Clin Immunol 2018;142:1679-1695
  10. Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N; Members of the CEREDIH French PID Study Group. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol 2017;140:1388-1393.e8
  11. Hadjadj J, Aladjidi N, Fernandes H, Leverger G, Magerus-Chatinet A, Mazerolles F, Stolzenberg MC, Jacques S, Picard C, Rosain J, Fourrage C, Hanein S, Zarhrate M, Pa